A Real-world, Retrospective Observational Study of Targeted Therapy in Metastatic Colorectal Cancer

Intervention1: NIL: NIL Primary outcome(s): Clinical profile & tumor characteristics of mCRC patients Usage pattern of targeted therapies (bevacizumab, cetuximab, and panitumumab) in mCRC patients Overall Response Rate (ORR) Clinical Benefit Rate (CBR) Progression Free Survival (PFS) Duration of Response (DoR) Overall Survival (OS) Adverse drug reactions associated with targeted therapyTimepoint: Baseline and follow up as per routine clinical practice